Determining the Susceptibility Pattern of Different Candida Species, Isolated From Hospitalized Immunocompromised Patients in Urmia Hospitals, to Antifungal Drugs
Author(s): Ebrahim Sadeghi, Mohammad Karamiyar, Amir Nasimfar, Maryam Ebrahimi
Resistance to fungal infections is increasing throughout the world, and this is especially important in immunocompromised patients. Infection with candida fungi species is one of the most important causes of fungal infections in these patients, able to cause complications and mortality. The purpose of this study was to determine the susceptibility of isolated candida species to systemic antifungal drugs in immunocompromised patients in Urmia. Two hundred patients with immune deficiencies were examined for Candida fungi infection in Urmia hospitals. After isolation of Candida species causing the infection, their susceptibility to amphotericin B, fluconazole, itraconazole, voriconazole, posaconazole and ketoconazole was investigated. Data were analyzed using SPSS21. Chi-square, Fisher's exact and Monte Carlo tests were used to compare the data. Out of the 200 patients with immune deficiencies, 45 (23%) of the patients showed infections due to Candida fungi species. The isolated species were albicans (68.9%), glabrata (13.3%), tropicalis, parapsilosis, krusei and kefyr (each 4.4%). Overall susceptibility to amphotericin B was 77.8%, fluconazole 55.6%, itraconazole 46.7%, voriconazole 91.1%, posaconazole 77.8%, and ketoconazole 40%. According to the results, Voriconazole is the best medicine for preventing or treating candidal infections in patients with immune deficiencies.